Spectral Medical Inc.

Spectral Medical focuses on the development and commercialization of products for the treatment of septic shock globally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative

Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the R&D

Products that are manufactured by other diagnostic companies. Incorporated in 1991 and headquartered in Toronto, Canada, Spectral Medical was formerly known as Spectral Diagnostics Inc. before rebranding in December 2014.